diazoxide has been researched along with Pulmonary Hypertension in 36 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diazoxide is the first line and only Federal Drug Agency approved pharmacological agent for the treatment of hyperinsulinism." | 9.30 | Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism. ( Hamby, T; Nedrelow, J; Reynolds, C; Thornton, P; Truong, L, 2019) |
| "Diazoxide, a drug used to treat hyperinsulinemic hypoglycemia (HH), is associated with pulmonary hypertension (PH), as reported by the US Food and Drug Administration." | 7.96 | Pulmonary Hypertension Following Increased Dosing of Diazoxide in an Infant. ( Hasegawa, S; Kimura, S; Ohnishi, Y; Okada, S; Suzuki, Y; Yasudo, H, 2020) |
| "Diazoxide is first-line treatment for hyperinsulinaemic hypoglycaemia (HH) but diazoxide-induced pulmonary hypertension (PH) can occur." | 7.91 | Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom. ( Aftab, S; Banerjee, I; Bath, L; Chen, SC; Christov, G; Dastamani, A; Giardini, A; Hunter, L; Pintus, D; Senniappan, S; Shah, P; Shaikh, MG; Swinburne, C; Yau, D, 2019) |
| " The relatively high prevalence of neutropenia, thrombocytopenia, and hyperuricemia suggests the value in proactively screening for these side effects in children treated with diazoxide." | 7.88 | Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide. ( Avitabile, CM; De León, DD; Givler, S; Herrera, A; Lord, K; Mitteer, L; Vajravelu, ME, 2018) |
| "Diazoxide is the main therapeutic agent for persistent hyperinsulinemic hypoglycemia." | 7.77 | Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. ( Arasli, A; Çetin, II; Demirel, F; Esen, I; Unal, S, 2011) |
| "Diazoxide is commonly used in the treatment of neonatal hyperinsulinism." | 7.74 | Development of pulmonary hypertension in an infant treated with diazoxide. ( Caldwell, RL; Eugster, EA; Hoover, WC; Nebesio, TD; Nitu, ME, 2007) |
| "Hemodynamic effects were studied after the administration of incremental doses of diazoxide (upper range 300-600 mg) in a group of 15 patients with severe pulmonary hypertension due to different etiologies." | 7.68 | [Effect of diazoxide on severe pulmonary hypertension]. ( Raimondi, GA, 1990) |
| "The use of diazoxide in the treatment of pulmonary hypertension has been advocated recently." | 7.66 | Hazards of diazoxide in pulmonary hypertension. ( Buch, J; Wennevold, A, 1981) |
| "Diazoxide was injected into the pulmonary artery in nine patients with primary pulmonary hypertension." | 7.66 | Clinical and haemodynamic effects of diazoxide in primary pulmonary hypertension. ( Cotter, L; Davies, N; Denison, D; Honey, M, 1980) |
| "Three patients with primary pulmonary hypertension and one man with suspected thromboembolic pulmonary hypertension were given up to 300 mg diazoxide by injection into the pulmonary artery." | 7.66 | Diazoxide in treatment of primary pulmonary hypertension. ( Pohl, JE; Rowlands, DJ; Wade, EG; Wang, SW, 1978) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 5.35 | Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. ( Erdem, S; Küçükosmanoglu, O; Yildizdas, D; Yilmaz, M; Yüksel, B, 2008) |
| "Diazoxide is the first line and only Federal Drug Agency approved pharmacological agent for the treatment of hyperinsulinism." | 5.30 | Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism. ( Hamby, T; Nedrelow, J; Reynolds, C; Thornton, P; Truong, L, 2019) |
| "When diazoxide was discontinued on two separate occasions pulmonary hypertension recurred." | 5.27 | Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide. ( Chan, NS; Kenmure, AC; McLay, J, 1987) |
| "Diazoxide, a drug used to treat hyperinsulinemic hypoglycemia (HH), is associated with pulmonary hypertension (PH), as reported by the US Food and Drug Administration." | 3.96 | Pulmonary Hypertension Following Increased Dosing of Diazoxide in an Infant. ( Hasegawa, S; Kimura, S; Ohnishi, Y; Okada, S; Suzuki, Y; Yasudo, H, 2020) |
| "Diazoxide is first-line treatment for hyperinsulinaemic hypoglycaemia (HH) but diazoxide-induced pulmonary hypertension (PH) can occur." | 3.91 | Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom. ( Aftab, S; Banerjee, I; Bath, L; Chen, SC; Christov, G; Dastamani, A; Giardini, A; Hunter, L; Pintus, D; Senniappan, S; Shah, P; Shaikh, MG; Swinburne, C; Yau, D, 2019) |
| " The relatively high prevalence of neutropenia, thrombocytopenia, and hyperuricemia suggests the value in proactively screening for these side effects in children treated with diazoxide." | 3.88 | Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide. ( Avitabile, CM; De León, DD; Givler, S; Herrera, A; Lord, K; Mitteer, L; Vajravelu, ME, 2018) |
| "Diazoxide is the main therapeutic agent for persistent hyperinsulinemic hypoglycemia." | 3.77 | Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. ( Arasli, A; Çetin, II; Demirel, F; Esen, I; Unal, S, 2011) |
| "Diazoxide is commonly used in the treatment of neonatal hyperinsulinism." | 3.74 | Development of pulmonary hypertension in an infant treated with diazoxide. ( Caldwell, RL; Eugster, EA; Hoover, WC; Nebesio, TD; Nitu, ME, 2007) |
| "Hemodynamic effects were studied after the administration of incremental doses of diazoxide (upper range 300-600 mg) in a group of 15 patients with severe pulmonary hypertension due to different etiologies." | 3.68 | [Effect of diazoxide on severe pulmonary hypertension]. ( Raimondi, GA, 1990) |
| "The use of diazoxide in the treatment of pulmonary hypertension has been advocated recently." | 3.66 | Hazards of diazoxide in pulmonary hypertension. ( Buch, J; Wennevold, A, 1981) |
| "Diazoxide was injected into the pulmonary artery in nine patients with primary pulmonary hypertension." | 3.66 | Clinical and haemodynamic effects of diazoxide in primary pulmonary hypertension. ( Cotter, L; Davies, N; Denison, D; Honey, M, 1980) |
| "Three patients with primary pulmonary hypertension and one man with suspected thromboembolic pulmonary hypertension were given up to 300 mg diazoxide by injection into the pulmonary artery." | 3.66 | Diazoxide in treatment of primary pulmonary hypertension. ( Pohl, JE; Rowlands, DJ; Wade, EG; Wang, SW, 1978) |
| "Pulmonary hypertension is frequently observed in some cardiac malformation and in congenital diaphragmatic hernia, in meconium aspiration syndrome, neonatal sepsis, podalic presentation and male sex." | 2.44 | Drug-induced pulmonary hypertension in newborns: a review. ( Camporesi, A; Silvani, P, 2007) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 1.35 | Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. ( Erdem, S; Küçükosmanoglu, O; Yildizdas, D; Yilmaz, M; Yüksel, B, 2008) |
| "When diazoxide was discontinued on two separate occasions pulmonary hypertension recurred." | 1.27 | Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide. ( Chan, NS; Kenmure, AC; McLay, J, 1987) |
| "Isosorbide dinitrate was the only drug that elicited any reduction in pulmonary artery pressure; pulmonary vascular resistance decreased modestly." | 1.26 | Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension. ( Bambach, D; Fontana, ME; Hermiller, JB; Huss, P; Leier, CV; Magorien, RD; Thompson, MJ; Unverferth, DV, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (72.22) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 5 (13.89) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SC | 1 |
| Dastamani, A | 1 |
| Pintus, D | 1 |
| Yau, D | 1 |
| Aftab, S | 1 |
| Bath, L | 1 |
| Swinburne, C | 1 |
| Hunter, L | 1 |
| Giardini, A | 1 |
| Christov, G | 1 |
| Senniappan, S | 1 |
| Banerjee, I | 1 |
| Shaikh, MG | 1 |
| Shah, P | 1 |
| Ohnishi, Y | 1 |
| Okada, S | 1 |
| Yasudo, H | 1 |
| Kimura, S | 1 |
| Suzuki, Y | 1 |
| Hasegawa, S | 1 |
| Timlin, MR | 1 |
| Black, AB | 1 |
| Delaney, HM | 1 |
| Matos, RI | 1 |
| Percival, CS | 1 |
| Herrera, A | 1 |
| Vajravelu, ME | 1 |
| Givler, S | 1 |
| Mitteer, L | 1 |
| Avitabile, CM | 1 |
| Lord, K | 1 |
| De León, DD | 1 |
| Thornton, P | 1 |
| Truong, L | 1 |
| Reynolds, C | 1 |
| Hamby, T | 1 |
| Nedrelow, J | 1 |
| Yildizdas, D | 1 |
| Erdem, S | 1 |
| Küçükosmanoglu, O | 1 |
| Yilmaz, M | 1 |
| Yüksel, B | 1 |
| Demirel, F | 1 |
| Unal, S | 1 |
| Çetin, II | 1 |
| Esen, I | 1 |
| Arasli, A | 1 |
| ROWE, GG | 1 |
| LEICHT, TR | 1 |
| BOAKE, WC | 1 |
| KYLE, JC | 1 |
| CRUMPTON, CW | 1 |
| Silvani, P | 1 |
| Camporesi, A | 1 |
| Nebesio, TD | 1 |
| Hoover, WC | 1 |
| Caldwell, RL | 1 |
| Nitu, ME | 1 |
| Eugster, EA | 1 |
| Peter, RH | 2 |
| Rubin, L | 1 |
| Cotter, L | 3 |
| Pannarale, G | 2 |
| Gaspardone, A | 2 |
| Acconcia, MC | 2 |
| Valente, A | 2 |
| Hall, DR | 2 |
| Rich, S | 1 |
| Martinez, J | 1 |
| Lam, W | 1 |
| Levy, PS | 1 |
| Rosen, KM | 1 |
| Berkenboom, G | 1 |
| Sobolski, J | 1 |
| Stoupel, E | 1 |
| Hermiller, JB | 1 |
| Bambach, D | 1 |
| Thompson, MJ | 1 |
| Huss, P | 1 |
| Fontana, ME | 1 |
| Magorien, RD | 1 |
| Unverferth, DV | 1 |
| Leier, CV | 1 |
| Buch, J | 1 |
| Wennevold, A | 1 |
| Reeves, JT | 1 |
| Klinke, WP | 2 |
| Gilbert, JA | 1 |
| Honey, M | 2 |
| Camerini, F | 1 |
| Alberti, E | 1 |
| Klugmann, S | 1 |
| Salvi, A | 1 |
| Davies, N | 1 |
| Denison, D | 1 |
| Rubin, LJ | 2 |
| Thomas, D | 1 |
| Drobinski, G | 1 |
| Komajda, M | 1 |
| Grosgogeat, Y | 1 |
| Elkayam, U | 1 |
| Rubino, JM | 1 |
| Schroeder, JS | 1 |
| Wang, SW | 1 |
| Pohl, JE | 1 |
| Rowlands, DJ | 1 |
| Wade, EG | 1 |
| Fleischmann, LE | 1 |
| Raimondi, GA | 1 |
| Hughes, JD | 1 |
| Petch, MC | 1 |
| Chan, NS | 1 |
| McLay, J | 1 |
| Kenmure, AC | 1 |
| Both, A | 1 |
5 reviews available for diazoxide and Pulmonary Hypertension
| Article | Year |
|---|---|
Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.
Topics: Congenital Hyperinsulinism; Diazoxide; Humans; Hypertension, Pulmonary; Infant, Newborn; Insulin Ant | 2017 |
Drug-induced pulmonary hypertension in newborns: a review.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Circulation; Diazoxide; Humans; Hypertension | 2007 |
The pharmacologic control of the pulmonary circulation in pulmonary hypertension.
Topics: Acetylcholine; Adult; Aminophylline; Calcium Channel Blockers; Diazoxide; Female; Humans; Hydralazin | 1984 |
[Early pulmonary hypertension: current therapeutic prospectives].
Topics: Calcium Channel Blockers; Captopril; Diazoxide; Diltiazem; Humans; Hydralazine; Hypertension, Pulmon | 1982 |
Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aminorex; Anticoagulants; Autoimmune Diseases; Calc | 1986 |
1 trial available for diazoxide and Pulmonary Hypertension
| Article | Year |
|---|---|
Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism.
Topics: Diazoxide; Female; Humans; Hyperinsulinism; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; | 2019 |
30 other studies available for diazoxide and Pulmonary Hypertension
| Article | Year |
|---|---|
Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom.
Topics: Congenital Hyperinsulinism; Diazoxide; Echocardiography; Female; Gestational Age; Humans; Hypertensi | 2019 |
Pulmonary Hypertension Following Increased Dosing of Diazoxide in an Infant.
Topics: Atrial Natriuretic Factor; Beckwith-Wiedemann Syndrome; Cardiac Catheterization; Congenital Hyperins | 2020 |
Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
Topics: Congenital Hyperinsulinism; Diazoxide; Dose-Response Relationship, Drug; Drug Administration Schedul | 2018 |
Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy.
Topics: Congenital Hyperinsulinism; Diazoxide; Female; Heart Failure; Humans; Hypertension, Pulmonary; Infan | 2008 |
Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide.
Topics: Diagnosis, Differential; Diazoxide; Ductus Arteriosus, Patent; Humans; Hyperinsulinism; Hypertension | 2011 |
THE SYSTEMIC AND CORONARY HEMODYNAMIC EFFECTS OF DIAZOXIDE.
Topics: Arrhythmias, Cardiac; Benzothiadiazines; Blood Circulation; Blood Pressure; Chlorothiazide; Coronary | 1963 |
Development of pulmonary hypertension in an infant treated with diazoxide.
Topics: Diazoxide; Female; Humans; Hyperinsulinism; Hypertension, Pulmonary; Hypoglycemia; Hypoglycemic Agen | 2007 |
Vasodilator treatment of primary pulmonary hypertension.
Topics: Administration, Oral; Adult; Diazoxide; Female; Humans; Hydralazine; Hypertension, Pulmonary; Middle | 1984 |
Remission of primary pulmonary hypertension during treatment with diazoxide.
Topics: Adult; Diazoxide; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Time Factors | 1981 |
Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response.
Topics: Adult; Blood Pressure; Cardiac Catheterization; Cardiac Output; Diazoxide; Female; Humans; Hydralazi | 1983 |
[Primary pulmonary hypertension: current therapeutic prospectives].
Topics: Calcium Channel Blockers; Diazoxide; Heart Rate; Humans; Hydralazine; Hypertension, Pulmonary; Isopr | 1982 |
Failure of nifedipine treatment in primary pulmonary hypertension.
Topics: Adult; Diazoxide; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pyridines | 1982 |
Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.
Topics: Adolescent; Adult; Aspirin; Diazoxide; Dipyridamole; Female; Hemodynamics; Humans; Hydralazine; Hype | 1982 |
Hazards of diazoxide in pulmonary hypertension.
Topics: Abdomen; Adolescent; Adult; Diazoxide; Female; Heart Arrest; Heart Block; Humans; Hypertension, Pulm | 1981 |
Hope in primary pulmonary hypertension.
Topics: Child; Diazoxide; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Pregnancy; Tim | 1980 |
Diazoxide in primary pulmonary hypertension.
Topics: Administration, Oral; Adult; Diazoxide; Drug Evaluation; Female; Hemodynamics; Humans; Hypertension, | 1980 |
Vasodilator therapy for pulmonary hypertension.
Topics: Administration, Oral; Diazoxide; Humans; Hypertension, Pulmonary | 1980 |
Treatment for primary pulmonary hypertension.
Topics: Diazoxide; Humans; Hypertension, Pulmonary; Isoproterenol; Oxygen Inhalation Therapy; Phentolamine | 1980 |
Primary pulmonary hypertension: effects of nifedipine.
Topics: Adult; Diazoxide; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Nifedipine; Pulmonary Arter | 1980 |
Clinical and haemodynamic effects of diazoxide in primary pulmonary hypertension.
Topics: Administration, Oral; Adult; Blood Pressure; Cardiac Catheterization; Diazoxide; Female; Humans; Hyp | 1980 |
Primary pulmonary hypertension: new approaches to therapy.
Topics: Diazoxide; Female; Humans; Hydralazine; Hypertension, Pulmonary; Phentolamine; Pregnancy | 1980 |
[Primary pulmonary arterial hypertension. Trial treatment with nifedipine, diazoxide and isoproterenol].
Topics: Diazoxide; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Isoproterenol; Middle | 1980 |
Vasodilator therapy in primary pulmonary hypertension.
Topics: Adult; Diazoxide; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Isoproterenol; | 1981 |
Diazoxide in treatment of primary pulmonary hypertension.
Topics: Adult; Diazoxide; Female; Humans; Hypertension, Pulmonary; Injections, Intra-Arterial; Pulmonary Art | 1979 |
Diazoxide in treatment of primary pulmonary hypertension.
Topics: Adult; Cardiac Output; Diazoxide; Female; Humans; Hypertension, Pulmonary; Injections, Intra-Arteria | 1978 |
Management of hypertensive crisis in children.
Topics: Acute Disease; Adolescent; Cerebrovascular Disorders; Child; Child, Preschool; Diazoxide; Humans; Hy | 1977 |
[Effect of diazoxide on severe pulmonary hypertension].
Topics: Adult; Aged; Blood Pressure; Diazoxide; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung | 1990 |
Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide.
Topics: Diazoxide; Female; Humans; Hypertension, Pulmonary | 1987 |
Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide.
Topics: Adult; Blood Pressure; Diazoxide; Female; Humans; Hypertension, Pulmonary; Pulmonary Artery | 1987 |
[Therapy of primary pulmonary hypertension].
Topics: Acetylcholine; Amino Alcohols; Carbachol; Child; Diazepam; Diazoxide; Female; Humans; Hypertension, | 1970 |